Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia

Journal of Clinical Oncology

Volumn 33, Issue 18, 2015, Pages 2072-2083

  Gale, Rosemary E ^a   Lamb, Katarina ^a   Allen, Christopher ^a   El Sharkawi, Dima ^a   Stowe, Cassandra ^a   Jenkinson, Sarah ^a   Tinsley, Steven ^a   Dickson, Glenda ^a   Burnett, Alan K ^b   Hills, Robert K ^b   Linch, David C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ARTICLE; PRIORITY JOURNAL; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; COHORT ANALYSIS; CPG ISLAND; EXON; FEMALE; GENETICS; GENOTYPE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; COHORT STUDIES; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENOTYPE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937576519     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.2022     Document Type: Article

References (38)

1. Cancer Genome Atlas Research Network: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059-2074, 2013
2. Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2010
3. Shen Y, Zhu YM, Fan X, et al: Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 118:5593-5603, 2011
4. Thol F, Damm F, Lüdeking A, et al: Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29:2889-2896, 2011
5. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al: Mutant DNMT3A: A marker of poor prognosis in acute myeloid leukemia. Blood 119:5824-5831, 2012
6. Renneville A, Boissel N, Nibourel O, et al: Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: A study by the Acute Leukemia French Association. Leukemia 26:1247-1254, 2012
7. Hou HA, Kuo YY, Liu CY, et al: DNMT3A mutations in acute myeloid leukemia: Stability during disease evolution and clinical implications. Blood 119:559-568, 2012
8. Marcucci G, Metzeler KH, Schwind S, et al: Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30:742-750, 2012
9. Gaidzik VI, Schlenk RF, Paschka P, et al: Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: Results of the AML Study Group (AMLSG). Blood 121:4769-4777, 2013
10. Marcucci G, Haferlach T, Döhner H: Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 29:475-486, 2011
11. Ofran Y, Rowe JM: Genetic profiling in acute myeloid leukaemia: Where are we and what is its role in patient management? Br J Haematol 160:303-320, 2013
12. Cornelissen JJ, Gratwohl A, Schlenk RF, et al: The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nat Rev Clin Oncol 9:579-590, 2012
13. O'Donnell MR, Abboud CN, Altman J, et al: Acute myeloid leukemia. J Natl Compr Canc Netw 10:984-1021, 2012
14. Shivarov V, Gueorguieva R, Stoimenov A, et al: DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leuk Res 37:1445-1450, 2013
15. Tie R, Zhang T, Fu H, et al: Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: A systematic review and meta-analysis. PloS One 9:e93353, 2014
16. Li KK, Luo LF, Shen Y, et al: DNA methyltransferases in hematologic malignancies. Semin Hematol 50:48-60, 2013
17. Yamashita Y, Yuan J, Suetake I, et al: Array-based genomic resequencing of human leukemia. Oncogene 29:3723-3731, 2010
18. Yan XJ, Xu J, Gu ZH, et al: Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43:309-315, 2011
19. Holz-Schietinger C, Matje DM, Reich NO: Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem 287:30941-30951, 2012
20. Kim SJ, Zhao H, Hardikar S, et al: A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 122:4086-4089, 2013
21. Russler-Germain DA, Spencer DH, Young MA, et al: The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25:442-454, 2014
22. Holz-Schietinger C, Matje DM, Harrison MF, et al: Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation. J Biol Chem 286:41479-41488, 2011
23. Kervestin S, Jacobson A: NMD: A multifaceted response to premature translational termination. Nat Rev Mol Cell Biol 13:700-712, 2012
24. Okano M, Bell DW, Haber DA, et al: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247-257, 1999
25. Tadokoro Y, Ema H, Okano M, et al: De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med 204:715-722, 2007
26. Challen GA, Sun D, Jeong M, et al: Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 44:23-31, 2012
27. Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
28. Gale RE, Green C, Allen C, et al: The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776-2784, 2008
29. Mead AJ, Linch DC, Hills RK, et al: FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110:1262-1270, 2007
30. Green CL, Koo KK, Hills RK, et al: Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: Impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 28:2739-2747, 2010
31. Green CL, Evans CM, Hills RK, et al: The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116:2779-2782, 2010
32. Green CL, Evans CM, Zhao L, et al: The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118:409-412, 2011
33. th AML trial (MRC AML10). Blood 89:2311-2318, 1997
34. Burnett AK, Hills RK, Milligan DW, et al: Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 28:586-595, 2010
35. Early Breast Cancer Trialists Collaborative Group: Treatment of Early Breast Cancer Volume I: Worldwide Evidence 1985-90. Oxford, United Kingdom, Oxford University Press, 1990
36. Blyth CR: On Simpson's paradox and the sure-thing principle. J Am Stat Assoc 67:364-366, 1972
37. Marcucci G, Maharry K, Wu YZ, et al: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355, 2010
38. Marková J, Michková P, Burèková K, et al: Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol 88:128-135, 2012